Related Experiment Video
Updated: May 26, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
[New developments in Sézary syndrome]
A Caudron1, A Marie-Cardine, A Bensussan
1Service de dermatologie, hôpital Sud, CHU d'Amiens, France. acaudron02@gmail.com
Sézary syndrome (SS), a rare cutaneous T-cell lymphoma (CTCL), has a poor prognosis. New diagnostic markers like KIR3DL2 and targeted therapies offer improved prospects for this aggressive disease.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Sézary syndrome (SS) is an aggressive form of cutaneous T-cell lymphoma (CTCL), accounting for 3% of cases.
- It is characterized by erythroderma, lymphadenopathy, and a high count of atypical T lymphocytes.
- The 5-year survival rate for SS is currently low, at 24%.
Purpose of the Study:
- To review the current understanding of Sézary syndrome (SS) in terms of its pathophysiology and therapeutic strategies.
- To highlight recent advancements in diagnostic markers and novel therapeutic approaches for SS.
- To discuss the potential of targeted therapies in improving the prognosis of SS.
Main Methods:
- Review of existing scientific literature on Sézary syndrome (SS).
- Analysis of diagnostic criteria, including the role of the KIR3DL2 (CD158k) receptor.
- Examination of current and emerging therapeutic strategies, including ongoing clinical trials.
Main Results:
- The identification of KIR3DL2 (CD158k) as a specific marker for Sézary cells aids in more accurate SS diagnosis.
- KIR3DL2 levels correlate strongly with the clinical progression of the disease.
- Emerging targeted therapies show promise for improving patient outcomes.
Conclusions:
- Sézary syndrome (SS) remains a challenging diagnosis with a significant mortality rate.
- Advances in understanding SS pathophysiology and the development of specific biomarkers like KIR3DL2 are crucial.
- New targeted therapies represent a promising avenue for improving the prognosis and treatment of Sézary syndrome.
More Related Videos
10:21Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
Published on: September 20, 2024
06:15Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Related Concept Videos
Cytotoxic Edema: Pathophysiology
Nephrotic Syndrome I : Introduction
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Graves Disease II: Pathophysiology
Nephrotic Syndrome II : Assessment and Medical Management
Targeted Cancer Therapies
There are several types of targeted therapies against specific...